Generic Name and Formulations:
Ticagrelor 60mg, 90mg; tabs.
Company:
AstraZeneca Pharmaceuticals
 
Select therapeutic use: Thromboembolic disorders
Indications for BRILINTA:
To reduce the rate of cardiovascular death, MI, and stroke in patients with acute coronary syndrome (ACS) or history of MI. To reduce the rate of stent thrombosis in patients who have been stented for ACS.

Adult:
Swallow whole; if unable to swallow, may crush tabs, then mix with water and drink or give via NG tube (CH8 or greater). Initially 180mg loading dose, continue with 90mg twice daily during the first year; after one year, give 60mg twice daily. After the initial loading dose of aspirin, take ticagrelor with maintenance dose of aspirin 75–100mg daily.

Children:
Not established.

Contraindications:
History of intracranial hemorrhage. Active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage).

Warnings/Precautions:
Increased risk of bleeding. Do not start in patients planned to undergo urgent CABG. Premature discontinuation increases risk for CV events (eg, MI, stroke, death). Avoid interruption of treatment; if temporarily discontinued, restart as soon as possible. When possible, interrupt therapy for 5 days prior to surgery (those with major bleeding risk); resume upon hemostasis. Effectiveness reduced with aspirin maintenance dose >100mg; avoid. History of sick sinus syndrome, 2nd or 3rd-degree AV block or bradycardia-related syncope without a pacemaker: increased risk of bradyarrhythmias. Moderate hepatic impairment. Severe hepatic impairment: avoid. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:
Concomitant other oral P2Y12 platelet inhibitor: not recommended. Avoid concomitant strong CYP3A inhibitors (eg, ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, telithromycin) or potent CYP3A inducers (eg, rifampin, phenytoin, carbamazepine, phenobarbital). Potentiates simvastatin, lovastatin; avoid >40mg/day doses. Monitor digoxin during ticagrelor initiation and dose adjustments.

Pharmacological Class:
P2Y12 platelet inhibitor (cyclopentyltriazolopyrimidine).

Adverse Reactions:
Bleeding (may be fatal), dyspnea (consider other alternatives if intolerable), dizziness, nausea, diarrhea; ventricular pauses.

Generic Availability:
NO

How Supplied:
Tabs 60mg—60; 90mg—14, 60